
Class action lawsuit launched over Disc Medicine's FDA drug rejection causing 22% stock drop
Disc Medicine, Inc. faced a 22% stock price drop after the FDA issued a Complete Response Letter rejecting its new drug application for bitopertin due to uncertainties requiring more evidence. The Rosen Law Firm is investigating potential securities ...


